RAC1 and neoplasm: Some of these diverse mechanisms for calmodulin to regulate KRas and Rac1 GTPases could provide therapeutic opportunity in cancer pathophysiology, in particular where aberrant KRas signalling drives Rac1-dependent activities that contribute to tumour progression.